PRPF31

Across TCGA pan-cancer cohorts, PRPF31 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPF31 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher PRPF31 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPF31 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, READ, and SKCM are the cancer types where PRPF31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	III,IV	0.137	0.790	<.001	15	view →
READ	OS	Median	All	0.281	0.823	<.001	9	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →
BRCA	OS	Median	All	0.167	0.579	.026	8	view →
UCEC	DFS	Median	All	0.954	0.622	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPF31–DLBC (DFS)

Open the DLBC breakdown →